Mizuho Securities Remains a Hold on Amgen (AMGN)

Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen (AMGNResearch Report) today and set a price target of $202.00. The company’s shares closed last Tuesday at $235.52.

According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 36.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $243.07.

See the top stocks recommended by analysts >>

Amgen’s market cap is currently $131.6B and has a P/E ratio of 22.93.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.

Read More on AMGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More